482 related articles for article (PubMed ID: 2572694)
21. Pharmacology of nebivolol.
Mangrella M; Rossi F; Fici F; Rossi F
Pharmacol Res; 1998 Dec; 38(6):419-31. PubMed ID: 9990650
[TBL] [Abstract][Full Text] [Related]
22. Involvement of nitric oxide in both central and peripheral haemodynamic effect of D/L-nebivolol and its enantiomers in rats.
Sacco G; Evangelista S; Criscuoli M; Goso C; Bigioni M; Binaschi M; Manzini S; Maggi CA
Eur J Pharmacol; 2005 Mar; 511(2-3):167-74. PubMed ID: 15792785
[TBL] [Abstract][Full Text] [Related]
23. [Effect of pretreatment with atenolol and propranolol on sympatho-adrenal and cardiovascular responses to acute insulin-induced hypoglycaemia in the hypertensive patient].
Cannella G; Picotti GB; Giambelli A; Scolari F; Cesura AM; Tosoni S; Maiorca R
G Ital Cardiol; 1982; 12(12):884-8. PubMed ID: 6763907
[TBL] [Abstract][Full Text] [Related]
24. Effects of betaxolol, propranolol, and atenolol on isoproterenol-induced beta-adrenoceptor responses.
Riddell JG; Shanks RG
Clin Pharmacol Ther; 1985 Nov; 38(5):554-9. PubMed ID: 2865028
[TBL] [Abstract][Full Text] [Related]
25. Acute effects of third generation β-blockers on short-term and beat-to-beat blood pressure variability in sinoaortic-denervated rats.
Bertera FM; Del Mauro JS; Lovera V; Chiappetta D; Polizio AH; Taira CA; Höcht C
Hypertens Res; 2013 Apr; 36(4):349-55. PubMed ID: 23364340
[TBL] [Abstract][Full Text] [Related]
26. Metabolic profile of beta-adrenoceptor-blocking action of befunolol.
Maruyama Y; Awaji T; Inoue M; Takeo S
Arch Int Pharmacodyn Ther; 1991; 311():73-88. PubMed ID: 1686392
[TBL] [Abstract][Full Text] [Related]
27. Cardiovascular protective effects of nebivolol in Zucker diabetic fatty rats.
Toblli J; Cao G; Rivas C; Munoz M; Giani J; Dominici F; Angerosa M
J Hypertens; 2010 May; 28(5):1007-19. PubMed ID: 20411618
[TBL] [Abstract][Full Text] [Related]
28. Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective beta 1-adrenergic antagonist.
Van de Water A; Janssens W; Van Neuten J; Xhonneux R; De Cree J; Verhaegen H; Reneman RS; Janssen PA
J Cardiovasc Pharmacol; 1988 May; 11(5):552-63. PubMed ID: 2455841
[TBL] [Abstract][Full Text] [Related]
29. Long-term treatment with nebivolol attenuates renal damage in Zucker diabetic fatty rats.
Toblli JE; Cao G; Giani JF; Muñoz MC; Angerosa M; Dominici FP
J Hypertens; 2011 Aug; 29(8):1613-23. PubMed ID: 21720265
[TBL] [Abstract][Full Text] [Related]
30. Nebivolol: comparison of the effects of dl-nebivolol, d-nebivolol, l-nebivolol, atenolol, and placebo on exercise-induced increases in heart rate and systolic blood pressure.
Van Nueten L; De Crée J
Cardiovasc Drugs Ther; 1998 Sep; 12(4):339-44. PubMed ID: 9825177
[TBL] [Abstract][Full Text] [Related]
31. Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension.
Kamp O; Sieswerda GT; Visser CA
Am J Cardiol; 2003 Aug; 92(3):344-8. PubMed ID: 12888152
[TBL] [Abstract][Full Text] [Related]
32. Effects of D-nebivolol and L-nebivolol on left ventricular systolic and diastolic function: comparison with D-L-nebivolol and atenolol.
Stoleru L; Wijns W; van Eyll C; Bouvy T; Van Nueten L; Pouleur H
J Cardiovasc Pharmacol; 1993 Aug; 22(2):183-90. PubMed ID: 7692155
[TBL] [Abstract][Full Text] [Related]
33. Nebivolol induces distinct changes in profibrosis microRNA expression compared with atenolol, in salt-sensitive hypertensive rats.
Ye H; Ling S; Castillo AC; Thomas B; Long B; Qian J; Perez-Polo JR; Ye Y; Chen X; Birnbaum Y
Hypertension; 2013 May; 61(5):1008-13. PubMed ID: 23460283
[TBL] [Abstract][Full Text] [Related]
34. The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study.
Rizos E; Bairaktari E; Kostoula A; Hasiotis G; Achimastos A; Ganotakis E; Elisaf M; Mikhailidis DP
J Cardiovasc Pharmacol Ther; 2003 Jun; 8(2):127-34. PubMed ID: 12808486
[TBL] [Abstract][Full Text] [Related]
35. Pharmacodynamic studies of beta adrenergic antagonism induced in man by propranolol and practolol.
Bodem G; Brammell HL; Weil JV; Chidsey CA
J Clin Invest; 1973 Apr; 52(4):747-54. PubMed ID: 4144332
[TBL] [Abstract][Full Text] [Related]
36. Cardiovascular and pharmacokinetic interactions between nicorandil and adjunctive propranolol, atenolol or diltiazem in conscious dogs.
Humphrey SJ
Methods Find Exp Clin Pharmacol; 1998 Nov; 20(9):779-91. PubMed ID: 10022032
[TBL] [Abstract][Full Text] [Related]
37. Effects of propranolol on the circulatory changes and mobilization of free fatty acids caused by isoproterenol.
Nakano J; Kusakari T; Berry JL
Arch Int Pharmacodyn Ther; 1966 Nov; 164(1):120-7. PubMed ID: 5972306
[No Abstract] [Full Text] [Related]
38. Effect of nebivolol on endothelial nitric oxide and peroxynitrite release in hypertensive animals: Role of antioxidant activity.
Mason RP; Kubant R; Jacob RF; Walter MF; Boychuk B; Malinski T
J Cardiovasc Pharmacol; 2006 Jul; 48(1):862-9. PubMed ID: 16891916
[TBL] [Abstract][Full Text] [Related]
39. Pharmacological properties of nebivolol in man.
Van Bortel LM; de Hoon JN; Kool MJ; Wijnen JA; Vertommen CI; Van Nueten LG
Eur J Clin Pharmacol; 1997; 51(5):379-84. PubMed ID: 9049578
[TBL] [Abstract][Full Text] [Related]
40. Blockade of isoprenaline-induced changes in plasma free fatty acids, immunoreactive insulin levels and plasma renin activity in healthy human subjects, by propranolol, pindolol, practolol, atenolol, metoprolol and acebutolol.
Harms HH; Gooren L; Spoelstra AJ; Hesse C; Verschoor L
Br J Clin Pharmacol; 1978 Jan; 5(1):19-26. PubMed ID: 23133
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
